Severe Congenital Sideroblastic Anemia: A Patient Guide

Severe Congenital Sideroblastic Anemia (CSA) is a rare genetic condition that begins in the very first months of life, fundamentally changing how a child’s body produces blood. In its most severe forms, such as those caused by a mutation in the SLC25A38 gene, the body’s red blood cell “factories” in the bone marrow are unable to complete an early step of making hemoglobin ^[1]. SLC25A38 is a transporter that moves glycine into the mitochondria; when this is impaired, heme synthesis stalls. While the body continues to absorb iron from the gut (often at increased rates because the anemia suppresses a hormone called hepcidin), it cannot use it to build the protein that carries oxygen; instead, that iron becomes trapped inside the developing cells, forming distinctive circles known as ring sideroblasts ^[2]. This leaves the child with a profound shortage of healthy red blood cells, leading to the fatigue, pallor, and growth challenges of severe anemia.

Because the condition is so rare, a priority for families is obtaining a precise genetic diagnosis. Knowing the exact gene involved helps distinguish CSA from other types of anemia and guides expectations for how the disease may behave over time ^[3]. For many infants with severe CSA, the mainstay of treatment is regular red blood cell transfusions, which provide the oxygen-carrying capacity the body cannot produce on its own ^[4]. These transfusions are life-sustaining, but they also contribute to a lifelong challenge: the management of iron overload.

(Important Note: Never give your child iron supplements unless specifically instructed by your hematology team, as their body already struggles with excess iron).

Managing iron is a cornerstone of living with CSA. Because the body absorbs excess iron from food and receives even more through transfusions, the excess iron can eventually settle in vital organs like the heart and liver ^[5]. Protecting these organs requires a dedicated team of specialists and a consistent routine of monitoring and medication, known as chelation therapy, to remove the extra iron ^[6]. This careful, long-term vigilance is essential to ensuring that the complications of the disease do not interfere with a child’s overall health and development.

While managing the anemia and iron levels is a significant commitment, there is also a path toward a potential cure. For children with the most severe, transfusion-dependent forms of the disease, early referral to discuss a hematopoietic stem cell transplant (HSCT) is recommended. HSCT offers the possibility of replacing the blood-building system with healthy donor cells, though it carries substantial risks ^[7]. Navigating this journey requires a strong partnership with a specialized care team, but with modern diagnostics and a clear management framework, families can move forward with a focused plan to support their child’s future.